Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies

Blood

Volumn 99, Issue 1, 2002, Pages 75-82

  Corradini, Paolo ^a,b   Tarella, Corrado ^c   Olivieri, Attilio ^c   Gianni, Alessandro M ^c   Voena, Claudia ^c   Zallio, Francesco ^c   Ladetto, Marco ^c   Falda, Michele ^c   Lucesole, Moira ^c   Dodero, Anna ^c   Ciceri, Fabio ^c   Benedetti, Fabio ^c   Rambaldi, Alessandro ^c   Sajeva, Maria R ^c   Tresoldi, Moreno ^c   Pileri, Alessandro ^c   Bordignon, Claudio ^c   Bregni, Marco ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; THIOTEPA;

ADULT; AGED; ALLOGRAFT; ARTICLE; BLOOD DISEASE; BLOOD DYSCRASIA; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEALTH PROGRAM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MANTLE CELL LYMPHOMA; MORTALITY; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT PLANNING;

EID: 0036093053     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.1.75     Document Type: Article

References (34)

1. Outcome after allogeneic bone marrow transplant for leukemia in older adults
2. Bone marrow transplantation in patients aged 45 years and older
3. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
4. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
5. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
6. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effect
7. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age
8. Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
9. In vivo CAMPATH-1 H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
10. Autografting followed bynonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma
11. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
12. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia following bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease
13. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation
14. Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18)
15. Thiotepa improves allogeneic bone marrow engraftment without enhancing stem cell depletion in irradiated mice
16. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: Impact on blood progenitor cell transplantation
17. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection
18. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphoma
19. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting
20. Molecular and clinical remissions in multiple myeloma: The role of autologous and allogeneic transplantation of hematopoietic cells
21. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action investigation of minimal residual disease in acute leukemia
22. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors
23. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation
24. Allogenic bone marrow transplantation for low-grade lymphoma
25. Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia
26. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): A series of 73 patients from the SFGM database
27. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease
28. Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome
29. Conventional hematopoietic stem cell transplants from identical or alternative donors are feasible in recipients relapsing after an autograft
30. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-α fusion m-RNA
31. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210BCR-ABL and p190BCR-ABL after allogeneic bone marrow transplantation for chronic myeloid leukemia: Increased mixed myeloid chimerism and p190 BCR-ABL detection precede cytogenetic relapse
32. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma
33. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation
34. Negative immunomagnetic ex-vivo purging combined to high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: Evidence for long-term clinical and molecular remissions